+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia



Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia



American Journal of Cardiology 82(1): 113-117



We compared the effects of cholesterol-lowering therapy on 2 patient groups genetically defined as heterozygous for familial hypercholesterolemia (FH), 5 with a deletion of exon 15 (FH(Tonami-1)), and 7 with a point mutation at codon 664 (FH(Kanazawa-2)). There were significant differences in both serum and low-density lipoprotein cholesterol reductions between the 2 groups after combination therapy with pravastatin and cholestyramine, and the overall effect of genotype on serial changes in both was significant.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 032205585

Download citation: RISBibTeXText

PMID: 9671018

DOI: 10.1016/s0002-9149(98)00230-6


Related references

Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS. Metabolism: Clinical and Experimental 40(10): 1074-1078, 1991

Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 112(20): 3168-3173, 2005

The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia. Circulation 136(9): 880-882, 2017

Significance of combined treatment with pravastatin probucol and cholestyramine for cholesterol reduction and xanthoma regression in patients with familial hypercholesterolemia. Japanese Circulation Journal 53(8): 902, 1989

Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism: Clinical and Experimental 54(6): 741-747, 2005

Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. Journal of Clinical Endocrinology and Metabolism 86(10): 4926-4932, 2001

The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients. Clinica Chimica Acta; International Journal of Clinical Chemistry 162(2): 221-227, 1987

Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia. Arteriosclerosis and Thrombosis 11(5): 1368-1375, 1991

Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. Journal of Laboratory and Clinical Medicine 114(5): 554-562, 1989

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126(20): 2408-2417, 2013

Comparison of low-density lipoprotein cholesterol lowering by pravastatin to <100 mg/dl versus >100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus. American Journal of Cardiology 89(7): 857-860, April 1, 2002

Comparison of low-density lipoprotein cholesterol lowering by pravastatin to <100 mg/dl versus >100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus. American Journal of Cardiology 89(7): 857-860, 2002

Effect of food on the low density lipoprotein cholesterol lowering response to twice daily pravastatin. Arteriosclerosis 8(5): 590A-591A, 1988

The association of low density lipoprotein receptor activity low density lipoprotein cholesterol level and clinical course in homozygous familial hypercholesterolemia. Metabolism Clinical & Experimental 34(3): 294-299, 1985

Treatment of familial hypercholesterolemia a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. Journal of Internal Medicine 228(3): 241-248, 1990